Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised prostate cancer: The ANZUP ENZARAD Trial (ANZUP 1303).

TPS5078 Background: Adjuvant androgen deprivation therapy (ADT) including a luteinising hormone releasing hormone analogue (LHRHA) is standard of care given before, during, and after radiotherapy for localised prostate cancer (PC) at high risk of recurrence. Enzalutamide is a new, second generation androgen receptor (AR) inhibitor that is more potent and binds with a higher affinity to the AR than conventional non-steroidal anti-androgens (NSAA), and improves survival in metastatic, castration-resistant PC. We hypothesise that the incorporation of enzalutamide in adjuvant ADT, given before, during, and after radiation therapy for localised PC at high risk of recurrence will further improve outcomes.The aim is to determine the effectiveness of enzalutamide as part of adjuvant ADT with a LHRHA in men planned for radiotherapy for localised PC at high risk of recurrence Methods: DESIGN Open label, randomised, stratified, 2-arm, phase 3 intergroup trial. ELIGIBILITY Localised PC, high risk of recurrence, suita...